![](https://cdn.benzinga.com/files/imagecache/2048x1536xUP/images/story/2022/earnings_image_6530.jpeg)
Salarius Pharmaceuticals (NASDAQ:SLRX) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Salarius Pharmaceuticals missed estimated earnings by 44.44%, reporting an EPS of $-0.13 versus an estimate of $-0.09.
Revenue was down $1.27 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 26.62% drop in the share price the next day.
Here's a look at Salarius Pharmaceuticals's past performance:
Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
---|---|---|---|---|
EPS Estimate | -0.08 | -0.06 | -0.06 | -0.05 |
EPS Actual | -0.09 | -0.08 | -0.07 | -0.06 |
Revenue Estimate | 430.00K | 1.16M | 1.28M | 1.37M |
Revenue Actual | 0 | 0 | 571.39K | 1.27M |
To track all earnings releases for Salarius Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.